Facebook Linkedin RSS Twitter Youtube
Home 2023

Regeneron

StockWatch: Regeneron’s All Ears for Hearing Loss Drug Developer
Drug Discovery

StockWatch: Regeneron’s All Ears for Hearing Loss Drug Developer

Effective IoT Infrastructure Critical for Digital Drug Firms
Bioprocessing

Effective IoT Infrastructure Critical for Digital Drug Firms

Top 25 Biotech Companies of 2023
A-Lists

Top 25 Biotech Companies of 2023

Molecular Scissors Are Making the Cut … in Clinical Trials
Genome Editing

Molecular Scissors Are Making the Cut … in Clinical Trials

StockWatch: COPD Data, Analysts, Treg Cell Therapy Deal Lift Regeneron
GEN Edge

StockWatch: COPD Data, Analysts, Treg Cell Therapy Deal Lift Regeneron

Double Dare: Exscientia Expands AI Platform into Antibody Design
Artificial Intelligence

Double Dare: Exscientia Expands AI Platform into Antibody Design

Supreme Court Grapples with the Enablement Standard for Functional Genus Patent Claims
GEN Edge

Supreme Court Grapples with the Enablement Standard for Functional Genus Patent Claims

StockWatch: Investors Weigh Genome Editing after Clinical Hold, Patient Death
Cancer

StockWatch: Investors Weigh Genome Editing after Clinical Hold, Patient Death

New Labs, New Funds: Activity Blossoms in the Leading U.S. Biopharma Clusters
Insights

New Labs, New Funds: Activity Blossoms in the Leading U.S. Biopharma Clusters

123...11Page 1 of 11
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.